NEW YORK (GenomeWeb) – Research-stage biopharmaceutical company Enzyvant said today it has partnered with PerkinElmer to offer diagnostic testing for Farber disease to patients and their medical providers.
To read the full story....
...and receive Daily News bulletins.
Already have a 360Dx or GenomeWeb account?
Login Now.
Don't have a 360Dx or GenomeWeb account?
Register for Free.